Genetic polymorphisms of cytochrome P4501A1 and oesophageal squamous-cell carcinoma in Taiwan by Wu, M-T et al.
Genetic polymorphisms of cytochrome P4501A1 and oesophageal
squamous-cell carcinoma in Taiwan
M-T Wu*
,1,2, J-M Lee
3, D-C Wu
4, C-K Ho
1,2, Y-T Wang
1, Y-C Lee
3, H-K Hsu
5 and E-L Kao
6
1Graduate Institute of Occupational Safety and Health, Kaohsiung Medical University, Taiwan;
2Department of Occupational Medicine, Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan;
3Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan;
4Department of Gastroenterology,
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;
5Department of Chest Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;
6Department of Chest Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Several in vitro studies have demonstrated that genetic polymorphisms result in functionally signiﬁcant changes in cytochrome
p4501A1 (either CYP1A1 MspIo rexon 7) but the few epidemiologic studies of these polymorphisms in oesophageal
squamous-cell carcinoma have been inconclusive. These inconclusive results motivated us to further examine the relationship
between CYP1A1 MspI and exon 7 polymorphisms and risk of oesophageal cancer. In total, 146 cases of oesophageal
squamous-cell-carcinoma and 324 control cases (a total of 470 cases) were genotyped from records at three Taiwan hospitals.
No signiﬁcant association was noted for the CYP1A1 MspI polymorphism variable between carcinoma and control cases. In
contrast, the frequency of Ile/Ile, Ile/Val, and Val/Val in exon 7 was 68 (46.6%), 62 (42.5%), and 16 (11.0%) in carcinoma cases
and 179 (55.3%), 127 (39.2%), and 18 (5.6%) in control cases, respectively. After factoring out other potential contributing
factors, patients with Val/Val showed a 2.48 (95% CT=1.15–5.34) greater risk of developing oesophageal cancer than those
with Ile/Ile. A slightly (albeit not signiﬁcantly) greater risk was identiﬁed in subjects with Ile/Val (OR=1.34; 95% CI=0.86–2.07).
These ﬁndings suggest that an exon 7 polymorphism, not a MspI polymorphism, in CYP1A1 may be pivotal in the development
of oesophageal cancer.
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The CYP1A1 gene code in the aryl hydrocarbon hydroxylase
(AHH) enzyme is closely associated with the metabolism of
polycyclic aromatic hydrocarbons (PAHs) carcinogens (Crofts
et al, 1994). Previous studies have suggested that variant alleles
of CYP1A1 MspI polymorphism are associated with malignan-
cies, particularly lung cancer (Kawarjiri et al, 1990; Nakachi et
al, 1991; Hayashi et al, 1992; Xu et al, 1996). As reported by
Bartsch et al (2000), no association was identiﬁed between
CYP1A1 MspI and exon 7 polymorphisms and oesophageal
cancer risk in a series of studies done on populations of Cauca-
sians and Japanese (Lucas et al, 1996; Hori et al, 1997; Morita
et al, 1997; van Lieshout et al, 1999). However, Nimura et al
(1997) studied 89 oesophageal carcinoma patients and 137
cancer-free control patients in an ethnically Chinese population
and reported that heavy smokers with Val/Val genotypes of
CYP1A1 exon 7 had a three-fold risk of developing oesophageal
cancer as compared to those with Ile/Ile genotypes. A subse-
quent study by Roth et al (2000) did not ﬁnd any signiﬁcant
effect of CYP1A1 exon 7 polymorphisms in 56 individuals with
mild or moderate squamous dysplasia and 56 control indivi-
duals (a relatively small sample size) from Linxian, a region
of high oesophageal cancer risk in China. Recently, Wang et
al (2002) genotyped 127 oesophageal cancer cases and 101
controls and found that individuals with the CYP1A1 Val/Val
genotype had a higher risk of developing oesophageal cancer
than those with Ile/Ile (OR=2.48, 95%CI=1.12–5.54). In view
of the apparently signiﬁcant inﬂuence of ethnicity in previous
studies, we have examined further the role of CYP1A1 MspI
and exon 7 polymorphisms in oesophageal cancer risk in
Taiwan.
MATERIALS AND METHODS
Selection of cases and controls
Over the four-year period of this study, we recruited 146 patients
with pathologically-proven oesophageal squamous-cell-carcinoma
undergoing treatment at three hospitals in Taiwan, including the
National Taiwan University Hospital, the Kaohsiung Medical
University Hospital, and the Kaohsiung Veterans General Hospi-
tal. Concurrently, the preventive medicine department at each
hospital did their best to also recruit 1–4 malignancy-free
subjects per recruited carcinoma patient as healthy controls
(n=324). Healthy control subjects were selected based on being
the same gender as the recruited carcinoma patient and being
in the hospital during the same time and of roughly the same
age (+3 years). Subjects in this study were interviewed by trained
interviewers using a standardized questionnaire to collect demo-
graphic and substance use (cigarette, alcohol, and areca)
information. This study was approved by National Taiwan
University’s IRB Hospital. Informed consent was obtained from
all subjects.
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The MspI polymorphism in the CYP1A1 3' ﬂanking region was
determined using PCR and RFLP (Wu et al, 1998). The DNA
sample was ampliﬁed with 2 primers: 5'-CAGTGAAGAGGTG-
TAGCCGC-3' (upstream) and 5'-TAGGAGTCTTGTCTCATGCC-
3' (downstream) (Perkin Elmer, Taipei, Taiwan). Ampliﬁcation
was performed by initial denaturation at 948C for 5 min, followed
by 30 cycles at 948C for 1 min, 618C for 1 min, 728C for 1 min,
and a ﬁnal extension at 728C for 7 min.
The 10-ml ampliﬁcation result was digested using 3 units MspI
(New England Biolabs, Beverly, MA, USA). When an MspI restric-
tion site was present, the fragment of 340 bp was digested into two
lengths of 140- and 200-bp. Homozygous wild-type individuals
lacked the 140- and 200-bp fragment, and heterozygous individuals
had three bands; homozygous-rare allele individuals lacked the
large parent band while showing the smaller bands.
CYP1A1 Ile/Val polymorphism
The BsrDI polymorphism in CYP1A1 exon 7 was determined using
PCR and RFLP, according to the method used by Cascorbi et al
(1996), albeit with slight modiﬁcations. The DNA sample was
ampliﬁed with two primers: 5'-CTGTCTCCCTCTGGTTACAG-
GAAGC-3' (upstream) and 5'-TTCCACCCGTTGCAGCAGGATA-
GCC-3' (downstream) (Perkin Elmer, Taipei, Taiwan). Ampliﬁca-
tion was performed by initial denaturation at 958C for 5 min,
followed by 35 cycles at 958C for 30 s, 73.58C for 30 s, 728C for
30 s, and a ﬁnal extension at 728C for 7 min. The ﬁnal product
was digested by BsrDI. When a BsrDI restriction site was present,
the fragment of 204-bp was digested into two lengths of 65- and
139-bp. Individuals with Ile/Ile had the 65- and 139-bp fragment,
heterozygous individuals had three bands; and individuals with
Val/Val retained the larger parent bands (204-bp).
Laboratory QA/QC
We included one positive control and one negative control samples
in each genotyping set (*10 samples). The positive control sample
was included to ensure complete digestion of the PCR product by
restriction enzymes. The negative control was placed with the same
reagents as those used with actual samples, with the exception of
DNA templates.
Statistical analysis
The gene frequency and Hardy-Weinberg equilibrium tests were
conducted, with results entered into multiple logistic regression
models to determine, after adjustments had been made for other
factors of inﬂuence, the level of association between CYP1A1 MspI
and exon 7 polymorphisms and oesophageal cancer risk. Factors of
inﬂuence (covariates) in the models included the variables of age
(465 years and 465 years), gender, education level (5college,
high school, and 4elementary school), and race (Fukienese, Main-
lander, and ‘other’). The data were analysed using the SAS
statistical package and all P-values were two-sided.
RESULTS
The mean age for carcinoma and control cases was 60.6 and 61.2
years, with an associated age range of 37 to 81 and 34 to 84 years,
respectively. The habitual use of cigarettes (P=0.03), alcohol
(P=0.03), and areca (P50.01) provided the most signiﬁcant
predictors of oesophageal cancer risk (Table 1).
The frequency of MspI polymorphism in wild-type, heterozygous
variant, and homozygous variant control cases was 136 (42.0%),
146 (45.1%), and 42 (13.0%), respectively. The gene frequency of
the variant allele was 35.5%. The frequency of Ile/Ile, Ile/Val, and
Val/Val in exon 7 among controls was 179 (55.3%), 127 (39.2%),
and 18 (5.6%), respectively. The gene frequency of the variant allele
(Val) was 25.2%. The distribution of the different genotypes in
both MspI and exon 7 polymorphisms among the 324 control cases
closely conformed to Hardy-Weinberg expected frequencies
(w
2=0.04; d.f.=2; P=0.98 and w
2=0.28; d.f.=2; P=0.87, respectively).
The frequency of Ile/Ile, Ile/Val, and Val/Val in exon 7 was 68
(46.6%), 62 (42.5%), and 16 (11.0%) in carcinoma cases and
179 (55.3%), 127 (39.2%), and 18 (5.6%) in control cases, respec-
tively. As lists of those genotypes with elevated oesophageal cancer
risk were similar both after adjusting only for substance use and
after adjusting for substance use along with age, gender, education,
and race, we present here the results for the latter category.
Compared to those with Ile/Ile, subjects carrying Val/Val had a
2.34-fold risk (95% CI=1.13–4.85) of developing oesophageal
cancer. After adjusting for other potential confounding factors,
the result remained similar (OR=2.48; 95% CI=1.15–5.34) (Table
2). The results show even a slightly greater risk after further adjust-
ing for MspI polymorphism (OR=2.71; 95% CI=1.75–6.38). A
slight, but not signiﬁcant, risk elevation was found in subjects with
Ile/Val both before and after adjusting for confounding factors
(OR=1.29 and 1.34; 95% CI=0.85–1.94 and 0.86–2.07, respec-
tively). In contrast, we found no signiﬁcant polymorphic effect of
CYP1A1 MspI on oesophageal cancer (Table 2).
DISCUSSION
The results of this study found that those cases with the CYP1A1
Val/Val genotype had a 2.34 times higher risk (95% CI=1.13–
4.85) of developing oesophageal cancer than those with the Ile/Ile
genotype. In contrast, the CYP1A1 MspI genetic polymorphism
was not found to be associated with elevated oesophageal cancer
risk. Several studies on ethnic Japanese populations reported no
association between CYP1A1 MspI and exon 7 polymorphisms
and risk of oesophageal cancer (Hori et al, 1997; Morita et al,
1997; van Lieshout et al, 1999). However, their small case popula-
E
p
i
d
e
m
i
o
l
o
g
y
Table 1 Demographic characteristics of oesophageal cancer
Variables Cases n (%) Controls n (%) P value
Gender
Male 133 (91.1) 298 (92.0) 0.75
Female 13 (8.9) 26 (8.0)
Age (in years)
465 97 (66.4) 214 (66.1) 0.93
465 49 (33.6) 110 (33.9)
Education
4primary school 34 (23.3) 103 (31.8) 0.15
High schools 33 (22.6) 59 (18.2)
5College 79 (54.1) 162 (50.0)
Race
Fukienese 114 (78.1) 257 (79.3) 0.93*
Mainlanders 28 (19.2) 57 (17.6)
Other 4 (3.1) 10 (2.7)
Cigarette smoker
Non-smoker 64 (43.8) 177 (54.6) 0.03
Smokers 82 (56.2) 147 (45.4)
Alcohol consumption
Non-drinkers 82 (56.2) 215 (66.4) 0.03
Drinkers 64 (43.8) 109 (33.6)
Areca consumption
Non-chewers 115 (78.8) 294 (90.7) 50.01
Chewers 31 (21.2) 30 (9.3)
*Fisher exact test.
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not be sufﬁcient to make a scientiﬁc determination regarding geno-
type signiﬁcance. Although Roth et al (2000) found no signiﬁcant
effect of CYP1A1 exon 7 polymorphisms on either the 56 indivi-
duals with mild or moderate squamous dysplasia or the 56
control cases from a high oesophageal cancer risk region with an
ethnic Chinese population, Nimura et al (1997) found subjects in
China with heavy smoking habits had a three times higher
frequency of the CYP1A1 Val/Val variant. Recently, Wang et al
(2002) also found that individuals with the CYP1A1 Val/Val geno-
type had a higher risk of developing oesophageal cancer than those
with the Ile/Ile (OR=2.48, 95% CI=1.12–5.54). Our ﬁndings
approximate the Wang et al (2002) ﬁndings.
Human cancers, e.g., gastrointestinal cancers, were suggested to
be the result of the activation of procarcinogens into carcinogens
(Nakajima et al, 1996). Murray et al (1994) and Nakajima et al
(1996) examined the expression of cytochrome P450s in human
esophagi with squamous-cell carcinomas. Both studies found that
the amount of cytochrome P450 1A1 expression in tumorous
tissue to be signiﬁcantly higher than that in non-tumorous tissues.
These two ﬁndings suggest that the inducible CYP1A1 gene might
contribute to oesophageal cancer development. In two in vitro
studies, Kiyohara et al (1996) examined the relationship between
AHH inducibility (3-methylcholanthrene (MC)-induced AHH
activity/non-induced AHH activity) and the frequency of CYP1A1
MspI and exon 7 polymorphisms in peripheral lymphocytes in 84
healthy Japanese male subjects in vitro. They found the age-
adjusted AHH inducibility (mean+standard error) of the wild-
type, heterozygous, and homozygous variants of the CYP1A1 MspI
gene to be 4.89+0.36, 4.82+0.29, and 13.61+1.44, respectively.
Furthermore, the homozygous variants had signiﬁcantly higher
AHH inducibility than the combined wild-type and heterozygous
variants. However, no association was found between AHH indu-
cibility and CYP1A1 exon 7 polymorphisms. In contrast, Crofts et
al (1994) measured gene expression levels and AHH enzymatic
activity levels of MspI and exon 7 polymorphisms in mitogen-
stimulated lymphocytes in 51 healthy subjects. They reported that
subjects with the exon 7 polymorphism (variant alleles) (n=12)
had a relative level of CYP1A1 mRNA inducibility (induced/basal)
of 9.0+1.7, versus 5.9+0.6 in people with the wild-type alleles
(n=39). However, variant genotypes at the MspI site had no effect
on CYP1A1 gene induction. Our results in this epidemiologic
study align more closely with those obtained by Crofts et al
(1994).
Our previous study found the prevalence (number) of homozy-
gous wild-types, heterozygous variants, and homozygous variants
in CYP1A1 MspI polymorphisms to be 42.5% (34), 42.5% (34),
and 15.0% (12), respectively, among 80 coke-oven workers (Wu
et al, 1998). This distribution parallels the control population
recruited for our present study, suggesting no potential selection
bias was present.
In summary, this study found CYP1A1 exon 7 (but not MspI)
polymorphism to be a factor in elevated oesophageal cancer risk.
This association suggests that carcinogen biotransformation may
be a contributing factor to the etiology of oesophageal squa-
mous-cell-carcinoma among the population in Taiwan.
ACKNOWLEDGEMENTS
This research was supported by grants from the Taiwan National
Science Council (NSC 90-2320-B-037-040 and NSC 90-2320-B-
037-052), the Taiwan National Health Research Institute (NHRI-
CN-IN-9007P), and the Faculty Research Innovation Fund of
Kaohsiung Medical University (Drs TF Chen and OL Chen).
REFERENCES
Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K (2000)
Genetic polymorphism of CYP genes, alone or in combination, as a risk
modiﬁer of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9:
3–28
Cascorbi I, Brockmoller J, Roots I (1996) A C4887A polymorphism in exon 7
of human CYP1A1: population frequency, mutation linkages, and impact
on lung cancer susceptibility. Cancer Res 56: 4965–4969
Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ
(1994) Functional signiﬁcance of different human CYP1A1 genotypes.
Carcinogenesis 15: 2961–2963
Hayashi S, Watanabe J, Kawarjiri K (1992) High susceptibility to lung cancer
analyzed in terms of combined genotype P4501A1 and Mu-class
glutathione-S-transferase genes. Jpn J Cancer Res 83: 866–870
Hori H, Kawano T, Endo M, Yuasa Y (1997) Genetic polymorphisms of
tobacco- and alcohol-related metabolizing enzymes and human oesopha-
geal squamous cell carcinoma susceptibility. J Clin Gastroenterol 25:
568–575
Kawarjiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J (1990)
Identiﬁcation of genetically high risk individuals to lung cancer by DNA
polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 263: 131–133
Kiyohara C, Hirohata T, Inutsuka S (1996) The relationship between aryl
hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J
Cancer Res 87: 18–24
E
p
i
d
e
m
i
o
l
o
g
y
Table 2 CYP1A1 genotypes and oesophageal cancer
CYP1A1 Cases n (%) Controls n (%) OR (95% CI) AOR (95% CI)
MspI
Wild-type 60 (41.1) 136 (42.0) 1.00 1.00
Heteroxygous variant 65 (44.5) 146 (45.1) 1.01 (0.66, 1.54) 0.98 (0.63, 1.53)
Homozygous variant 21 (14.4) 42 (13.0) 1.13 (0.62, 2.08) 1.24 (0.65, 2.36)
Exon 7*
Ile/Ile 68 (46.6) 179 (55.3) 1.00 1.00
Ile/Val 62 (42.5) 127 (39.2) 1.29 (0.85, 1.94) 1.34 (0.86, 2.07)
Val/Val 16 (11.0) 18 (5.6) 2.34 (1.13, 4.85) 2.48 (1.15, 5.34)
AOR: After adjusting for age (465 vs 465 yrs), education level (4primary school, high school, 5college), ethnicity (Fukienese, Mainlander, Other), cigarette habit (yes vs no),
alcohol consumption (yes vs no), and areca consumption (yes vs no). *Trend test, P=0.02.
CYP1A1 and oesophageal cancer
M-T Wu et al
531
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(5), 529–532Lucas D, Menez C, Floch F, Gourlaouen Y, Sparfel O, Joannet I, Bodenez P,
Jezequel J, Gouerou H, Berthou F, Bardou LG, Menez JF (1996) Cyto-
chromes P4502E1 and P4501A1 genotypes and susceptibility to cirrhosis
or upper aerodigestive tract cancer in alcoholic caucasians. Alcohol Clin
Exp Res 20: 1033–1037
Morita S, Yano M, Shiozaki H, Tsujinaka T, Ebisui C, Morimoto T, Kishibuti
M, Fujita J, Ogawa A, Taniguchi M, Inoue M, Tamura S, Yamazaki K,
Kikkawa N, Mizunoya S, Monden M (1997) CYP1A1, CYP2E1 and
GSTM1 polymorphisms are not associated with susceptibility to squa-
mous-cell carcinoma of the esophagus. Int J Cancer 71: 192–195
Murray GI, Shaw D, Weaver RJ, McKay JA, Ewen SW, Melvin WT, Burke
MD (1994) Cytochrome P450 expression in oesophageal cancer. Gut 35:
599–603
Nakachi K, Imai K, Hayashi S, Watanabe J, Kawarjiri K (1991) Genetic
susceptibility to squamous cell carcinoma of the lung in relation to cigar-
ette smoking dose. Cancer Res 51: 5177–5180
Nakajima T, Wang RS, Nimura Y, Pin YM, He M, Vainio H, Murayama N,
Aoyama T, Iida F (1996) Expression of cytochrome P450s and glutathione
S-transferases in human esophagus with squamous-cell carcinomas. Carci-
nogenesis 17: 1477–1481
Nimura Y, Yokoyama S, Fujimori M, Aoki T, Adachi W, Nasu T, He M, Ping
YM, Iida F (1997) Genotyping of the CYP1A1 and GSTM1 genes in oeso-
phageal carcinoma patients with special reference to smoking. Cancer 80:
852–857
Roth MJ, Dawsey SM, Wang G, Tangrea JA, Zhou B, Ratnasinghe D, Wood-
son KG, Olivero OA, Poirier MC, Frye BL, Taylor PR, Weston A (2000)
Association between GSTM1*0 and squamous dysplasia of the esophagus
in the high risk region of Linxian, China. Cancer Lett 156: 73–81
van Lieshout EM, Roelofs HM, Dekker S, Mulder CJ, Wobbes T, Jansen JB,
Peters WH (1999) Polymorphic expression of the glutathione S-transferase
P1 gene and its susceptibility to Barrett’s esophagus and oesophageal carci-
noma. Cancer Res 59: 586–589
Wang AH, Sun CS, Li LS, Huang JY, Chen QS (2002) Relationship of tobacco
smoking CYP1A1 GSTM1 gene polymorphism and oesophageal cancer in
Xi’an. World J Gastroenterol 8: 49–53
Wu MT, Huang SL, Ho CK, Yeh YF, Christiani DC (1998) Cytochrome P450
1A1 MspI polymorphism and urinary 1-hydroxypyrene concentrations in
coke-oven workers. Cancer Epidemiol Biomarkers Prev 7: 823–829
Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC (1996) Cytochrome
P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer
Epidemiol Biomark Prev 5: 687–692
E
p
i
d
e
m
i
o
l
o
g
y
CYP1A1 and oesophageal cancer
M-T Wu et al
532
British Journal of Cancer (2002) 87(5), 529–532 ã 2002 Cancer Research UK